AZNAstraZenecaRunning, no new patients
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Breast Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 644 (final count)
- Started
- May 16, 2022
- Main results expected
- Aug 25, 2025
- Fully finished
- Dec 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)
Overall Survival (OS)
Measured over: From randomisation until the date of death due to any cause (approximately 42 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-08-25, no fading
Raw record changes
- none yet
Trial ID NCT05374512 · record last updated 2026-05-15 · checked 2026-11-09 15:47 UTC